NCCN Risk Reclassification in Black Men with Low and Intermediate Risk Prostate Cancer After Genomic Testing.
Benjamin Seiden1, Stanley Weng1, Natalie Sun2
1SUNY Downstate Health Sciences University, College of Medicine, Brooklyn, NY; Department of Urology, SUNY Downstate Health Sciences University, Brooklyn, NY; Department of Urology, Kings County Hospital Center, Brooklyn, NY.
Genomic testing significantly increased risk classifications for Black men with early prostate cancer, aiding personalized treatment decisions. This approach helps refine risk stratification for better management of prostate cancer in this population.
Area of Science:
- Oncology
- Genomics
- Urology
Background:
- Prostate cancer risk stratification is crucial for treatment decisions.
- Genomic testing offers a potential tool to refine risk assessment.
Purpose of the Study:
- To evaluate the utility of genomic testing in risk-stratifying Black patients with low and intermediate-risk prostate cancer.
Main Methods:
- Retrospective analysis of 63 Black men undergoing OncotypeDx Genomic Prostate Score testing.
- Comparison of National Comprehensive Cancer Network (NCCN) risk classifications before and after genomic testing.
Main Results:
- Genomic testing led to significantly higher NCCN risk classifications (P=.003).
- 70% of patients with discordant results were reclassified to a higher risk category.
- 64.5% of favorable intermediate-risk patients were reclassified to a higher risk category.
Conclusions:
- Genomic testing enhances risk stratification for Black men with low and intermediate-risk prostate cancer.
- Increased utilization of genomic testing can inform individualized treatment decisions.
More Related Videos
07:59Author Spotlight: Advancements in Molecular Biomarker Testing for Non-Squamous Non-Small Cell Lung Cancer
Published on: September 8, 2023
06:46Competing-Risk Nomogram for Predicting Cancer-Specific Survival in Multiple Primary Colorectal Cancer Patients after Surgery
Published on: September 27, 2024